Pancreatic Cancer Research

ResearcherGerman Cancer Research CenterActive in the last 2 years

Beatrice Mohelníková-Duchoňová

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0002-0935-2681; OpenAlex author ID A5109187523. Sources: OpenAlex.

Their work

Papers
51 (first author 0, last author 7)
Trials
0
Grants
0
Labs led
1
Collaborators
103
Papers, trials and grants by year

2011: 1 paper · 2012: none · 2013: 5 papers · 2014: 1 paper · 2015: 2 papers · 2016: 3 papers · 2017: 4 papers · 2018: 2 papers · 2019: 6 papers · 2020: 1 paper · 2021: 7 papers · 2022: 2 papers · 2023: 7 papers · 2024: 3 papers · 2025: 4 papers · 2026: 3 papers

Papers 50 of 51

  1. Benzoyl chloride derivatization improves selectivity and sensitivity of lipidomic quantitation in human serum of pancreatic cancer patients using RP-UHPLC/MS/M… Co-author DOI 10.1007/s00216-025-06151-0↗
  2. RP-UHPLC/MS/MS provides enhanced lipidomic profiling of human serum in pancreatic cancer. Co-author DOI 10.1016/j.aca.2025.344952↗
  3. Pilot study of screening method for pancreatic cancer using lipidomic profiling of plasma or serum. Co-author DOI 10.1038/s43856-026-01445-5↗
  4. Polymorphisms within autophagy-related genes as susceptibility biomarkers for pancreatic cancer: A meta-analysis of three large European cohorts and functional… Co-author DOI 10.1002/ijc.35196↗
  5. Potential for Clinical Management of Pancreatic Cancer Through Whole Exome Profiling of Site-Specific Metastases and Matched Primary Tumors. Co-author DOI 10.1016/j.labinv.2025.104205↗
  6. Therapeutic pancreatic cancer biomarkers and pharmacogenetics. Last author DOI 10.1016/j.semcancer.2025.08.002↗
  7. A pleiotropy scan to discover new susceptibility loci for pancreatic ductal adenocarcinoma. Co-author DOI 10.1093/mutage/geae012↗
  8. Potential association between PSCA rs2976395 functional variant and pancreatic cancer risk. Co-author DOI 10.1002/ijc.35046↗
  9. Stereotactic Radiotherapy Plus Nivolumab in Patients with Locally Advanced Pancreatic Cancer: Results from Phase 1/2 Clinical CA209-9KH Trial. Co-author DOI 10.1007/s40487-024-00309-z↗
  10. Polymorphisms in transcription factor binding sites and enhancer regions and pancreatic ductal adenocarcinoma risk. Co-author DOI 10.1186/s40246-024-00576-x↗
  11. Association between a polymorphic variant in the CDKN2B-AS1/ANRIL gene and pancreatic cancer risk. Co-author DOI 10.1002/ijc.34383↗
  12. The PANcreatic Disease ReseArch (PANDoRA) consortium: Ten years' experience of association studies to understand the genetic architecture of pancreatic cancer. Co-author DOI 10.1016/j.critrevonc.2023.104020↗
  13. Genetic and non-genetic risk factors for early-onset pancreatic cancer. Co-author DOI 10.1016/j.dld.2023.02.023↗
  14. Protein expression and localization of ABC transporters in pancreatic adenocarcinoma: Prognostic role of ABCC8. Co-author DOI 10.1016/j.pan.2023.10.008↗
  15. A scan of all coding region variants of the human genome, identifies 13q12.2-rs9579139 and 15q24.1-rs2277598 as novel risk loci for pancreatic ductal adenocarc… Co-author DOI 10.1093/carcin/bgad056↗
  16. Polymorphic variants involved in methylation regulation: a strategy to discover risk loci for pancreatic ductal adenocarcinoma. Co-author DOI 10.1136/jmg-2022-108910↗
  17. Exploring the Neandertal legacy of pancreatic ductal adenocarcinoma risk in Eurasians. Co-author DOI 10.1186/s40659-023-00457-y↗
  18. Common variability in oestrogen-related genes and pancreatic ductal adenocarcinoma risk in women. Co-author DOI 10.1038/s41598-022-22973-9↗
  19. Isolated Gastric Metastases of Pancreatic Ductal Adenocarcinoma following Radical Resection-Impact of Endosonography-Guided Fine Needle Aspiration Tract Seedin… Co-author DOI 10.3390/biomedicines10061392↗
  20. Lack of association of CD44-rs353630 and CHI3L2-rs684559 with pancreatic ductal adenocarcinoma survival. Co-author DOI 10.1038/s41598-021-87130-0↗
  21. Associations between pancreatic expression quantitative traits and risk of pancreatic ductal adenocarcinoma. Co-author DOI 10.1093/carcin/bgab057↗
  22. Polygenic and multifactorial scores for pancreatic ductal adenocarcinoma risk prediction. Co-author DOI 10.1136/jmedgenet-2020-106961↗
  23. Genetic Polymorphisms Involved in Mitochondrial Metabolism and Pancreatic Cancer Risk. Co-author DOI 10.1158/1055-9965.epi-21-0353↗
  24. Association of Genetic Variants Affecting microRNAs and Pancreatic Cancer Risk. Co-author DOI 10.3389/fgene.2021.693933↗
  25. Identification of Recessively Inherited Genetic Variants Potentially Linked to Pancreatic Cancer Risk. Co-author DOI 10.3389/fonc.2021.771312↗
  26. Gene expression of cytokinesis regulators PRC1, KIF14 and CIT has no prognostic role in colorectal and pancreatic cancer. Co-author DOI 10.3892/ol.2021.12859↗
  27. Genome-wide association study identifies an early onset pancreatic cancer risk locus. Co-author DOI 10.1002/ijc.33004↗
  28. Genetic determinants of telomere length and risk of pancreatic cancer: A PANDoRA study. Co-author DOI 10.1002/ijc.31928↗
  29. Germline BRCA2 K3326X and CHEK2 I157T mutations increase risk for sporadic pancreatic ductal adenocarcinoma. Co-author DOI 10.1002/ijc.32127↗
  30. Protein expression of ABCC2 and SLC22A3 associates with prognosis of pancreatic adenocarcinoma. Co-author DOI 10.1038/s41598-019-56059-w↗
  31. KRAS pathway expression changes in pancreatic cancer models by conventional and experimental taxanes. Co-author DOI 10.1093/mutage/gez021↗
  32. Genetic analysis of subsequent second primary malignant neoplasms in long-term pancreatic cancer survivors suggests new potential hereditary genetic alteration… Last author DOI 10.2147/cmar.s185352↗
  33. Biomarkers and pathways of chemoresistance and chemosensitivity for personalized treatment of pancreatic adenocarcinoma. Last author DOI 10.2217/pgs-2018-0073↗
  34. Do pancreatic cancer and chronic pancreatitis share the same genetic risk factors? A PANcreatic Disease ReseArch (PANDoRA) consortium investigation. Co-author DOI 10.1002/ijc.31047↗
  35. Genome-wide meta-analysis identifies five new susceptibility loci for pancreatic cancer. Co-author DOI 10.1038/s41467-018-02942-5↗
  36. SLC22A3 polymorphisms do not modify pancreatic cancer risk, but may influence overall patient survival. Co-author DOI 10.1038/srep43812↗
  37. Hedgehog pathway overexpression in pancreatic cancer is abrogated by new-generation taxoid SB-T-1216. Co-author DOI 10.1038/tpj.2016.55↗
  38. Different clinical presentations of metachronous pulmonary metastases after resection of pancreatic ductal adenocarcinoma: Retrospective study and review of th… Last author DOI 10.3748/wjg.v23.i35.6420↗
  39. Dysregulation of KRAS signaling in pancreatic cancer is not associated with KRAS mutations and outcome. Last author DOI 10.3892/ol.2017.6946↗
  40. Therapeutic potential of taxanes in the treatment of metastatic pancreatic cancer. Last author DOI 10.1007/s00280-016-3058-y↗
  41. Association of genetic polymorphisms with survival of pancreatic ductal adenocarcinoma patients. Co-author DOI 10.1093/carcin/bgw080↗
  42. Functional single nucleotide polymorphisms within the cyclin-dependent kinase inhibitor 2A/2B region affect pancreatic cancer risk. Co-author DOI 10.18632/oncotarget.10935↗
  43. TERT gene harbors multiple variants associated with pancreatic cancer susceptibility. Co-author DOI 10.1002/ijc.29590↗
  44. Common variation at 2p13.3, 3q29, 7p13 and 17q25.1 associated with susceptibility to pancreatic cancer. Co-author DOI 10.1038/ng.3341↗
  45. Role of solute carrier transporters in pancreatic cancer: a review. Last author DOI 10.2217/pgs.14.80↗
  46. The association between the expression of solute carrier transporters and the prognosis of pancreatic cancer. Co-author DOI 10.1007/s00280-013-2246-2↗
  47. Human equilibrative nucleoside transporter 1 (hENT1): do we really have a new predictive biomarker of chemotherapy outcome in pancreatic cancer patients? Co-author DOI 10.1016/j.pan.2013.09.005↗
  48. Differences in transcript levels of ABC transporters between pancreatic adenocarcinoma and nonneoplastic tissues. Co-author DOI 10.1097/mpa.0b013e318279b861↗
  49. Lack of replication of seven pancreatic cancer susceptibility loci identified in two Asian populations. Co-author DOI 10.1158/1055-9965.epi-12-1182↗
  50. ABO blood groups and pancreatic cancer risk and survival: results from the PANcreatic Disease ReseArch (PANDoRA) consortium. Co-author DOI 10.3892/or.2013.2285↗

Closest collaborators

The 25 strongest of 103 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Pavel Souček · 21 shared papers, 2011–2025 · strength 1.88
  2. Martin Loveček · 10 shared papers, 2017–2026 · strength 1.62
  3. Bohuslav Melichar · 12 shared papers, 2013–2026 · strength 1.62
  4. Ondřej Peterka · 3 shared papers, 2026 · strength 0.83
  5. Michal Holčapek · 3 shared papers, 2026 · strength 0.83
  6. Viktor Hlaváč · 6 shared papers, 2013–2025 · strength 0.71
  7. Daniele Campa · 8 shared papers, 2013–2025 · strength 0.67
  8. Zuzana Lásko · 2 shared papers, 2026 · strength 0.59
  9. Martin Oliverius · 9 shared papers, 2013–2022 · strength 0.58
  10. Lenka Červenková · 3 shared papers, 2019–2025 · strength 0.52
  11. Aleš Langer · 2 shared papers, 2025 · strength 0.46
  12. Milan Vošmik · 2 shared papers, 2024–2026 · strength 0.45
  13. Federico Canzian · 7 shared papers, 2013–2023 · strength 0.43
  14. Gabriele Capurso · 7 shared papers, 2013–2023 · strength 0.43
  15. Raffaele Pezzilli · 7 shared papers, 2013–2023 · strength 0.43
  16. Francesca Tavano · 5 shared papers, 2016–2023 · strength 0.38
  17. Radmila Lemstrová · 6 shared papers, 2014–2017 · strength 0.37
  18. Cosmeri Rizzato · 5 shared papers, 2013–2025 · strength 0.37
  19. Zdeněk Kala · 6 shared papers, 2013–2021 · strength 0.35
  20. Ștefania Bunduc · 2 shared papers, 2023–2025 · strength 0.35
  21. Riccardo Farinella · 2 shared papers, 2023–2025 · strength 0.35
  22. John P. Neoptolemos · 5 shared papers, 2013–2023 · strength 0.34
  23. Renata Talar‐Wojnarowska · 6 shared papers, 2013–2022 · strength 0.32
  24. Giulia Martina Cavestro · 3 shared papers, 2021–2023 · strength 0.29
  25. Giuseppe Vanella · 3 shared papers, 2021–2023 · strength 0.29

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.